Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
Sarepta Therapeutics (SRPT) Stock Price & Analysis
2,907 Followers
SRPT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$55.25 - $173.25
Previous Close$156.75
Volume1.33M
Average Volume (3M)1.76M
Market Cap
$14.82B
Enterprise Value$14.81B
Total Cash (Recent Filing)$1.39B
Total Debt (Recent Filing)$1.38B
Price to Earnings (P/E)2357.1
Beta0.70
Next Earnings
Jul 31, 2024EPS Estimate
-$0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding94,523,766
10 Day Avg. Volume2,709,603
30 Day Avg. Volume1,763,074
Standard Deviation0.16
R-Squared0.10
Alpha0.00505
Financial Highlights & Ratios
Price to Book (P/B)16.30
Price to Sales (P/S)38.29
Price to Cash Flow (P/CF)-15.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.55
Enterprise Value/Gross Profit13.55
Enterprise Value/Ebitda101.19
Forecast
1Y Price Target
$199.94Price Target Upside29.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
Sarepta Therapeutics News
Bulls Say, Bears Say
Bulls Say
Manufacturing EfficiencyElevidys likely won't face supply constraints as 75% of sites are already treating patients, heavier patients don't need extra drug, and new manufacturing processes will be about 10 times more efficient.
Market PotentialSarepta is in an unprecedentedly favorable position to monopolize the DMD market, potentially driving $30 billion in total Elevidys US sales from the prevalent population and $1 billion per year from new cases.
Regulatory MilestonesFDA granted full approval to Elevidys for ambulatory patients four or older, and on an accelerated basis for non-ambulatory patients, providing a broad label that drives potential market expansion.
Bears Say
Financial PerformanceRevenues for Exondys, Amondys and Vyondys are expected to decline over the next few years as patients look to switch to receive Elevidys.
Investor ConfidenceLack of announcement around Elevidys label is triggering increasing investor concerns due to speculations that FDA's decision may be delayed beyond 6/21.
Regulatory ChallengesMandatory 3 month monitoring of treated patients may pose a challenge.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SRPT FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $55.25 and its highest was $173.25 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Currently, no data Available
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Jul 31, 2024 which is in 28 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on May 01, 2024. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of $0.013 by $0.357.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is -$0.13.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 94,523,766 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of $0.37 in its last earnings report, beating expectations of $0.013. Following the earnings report the stock price went down -0.206%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Among the largest hedge funds holding Sarepta Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Sarepta Therapeutics’s shares valued at 318M.
---
Sarepta Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$199.94 (29.66% Upside)
$199.94 (29.66% Upside)
Blogger Sentiment
Bullish
SRPT Sentiment 93%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.6%
Last 30 Days ▲ 11.5%
Last 30 Days ▲ 11.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.87%
12-Months-Change
Fundamentals
Return on Equity
2.02%
Trailing 12-Months
Asset Growth
5.38%
Trailing 12-Months
Company Description
Sarepta Therapeutics
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
---
SRPT Earnings Call
Q1 2024
0:00 / 0:00
---
SRPT Stock 12 Month Forecast
Average Price Target
$199.94
▲(29.66% Upside)
Technical Analysis
Best Analysts Covering SRPT
1 Year
---